Clinical Screening for Ultraviolet Light Burn

Phase-Based Progress Estimates
University of Michigan, Ann Arbor, MI
Ultraviolet Light Burn
Ultra Violet Light Exposure - Other
18 - 65
What conditions do you have?

Study Summary

Pilot study to investigate the impact of exposure of human skin to low levels of UV light on blood markers related to stress in healthy women. Positive findings may serve to reframe the importance of skin health and skin care within the paradigm of holistic health and well-being.

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Ultraviolet Light Burn

Study Objectives

4 Primary · 1 Secondary · Reporting Duration: 1 week

1 week
Adverse events
Blood pressure
Dose frequency of UV light exposure
Heart rate
Interleukin 1 alpha (ng/ml)
Interleukin 10 (ng/ml)
Interleukin 6 (ng/ml)
Tumour Necrosis Factor alpha (ng/ml)

Trial Safety

Safety Progress

1 of 3

Other trials for Ultraviolet Light Burn

Trial Design

1 Treatment Group

Clinical Screening
1 of 1
Experimental Treatment

20 Total Participants · 1 Treatment Group

Primary Treatment: Clinical Screening · No Placebo Group · Phase < 1

Clinical Screening
Experimental Group · 1 Intervention: Ultra Violet Light Exposure · Intervention Types: Other

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 1 week
Closest Location: University of Michigan · Ann Arbor, MI
Photo of university of michigan comprehensive cancer center  1Photo of university of michigan comprehensive cancer center  2Photo of university of michigan comprehensive cancer center  3
2022First Recorded Clinical Trial
1 TrialsResearching Ultraviolet Light Burn
1003 CompletedClinical Trials

Eligibility Criteria

Age 18 - 65 · Female Participants · 8 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You do not smoke or use tobacco or nicotine-containing products of any kind, including vaping.
You are willing to maintain your usual diet and physical activity patterns during the study period.
You are of sound mind and body, and you are not suffering from any health condition that would prevent you from fulfilling the study requirements as judged by the study Investigator based on evaluation of medical history and routine laboratory test results.
You must be between 20 and 50 years of age to participate in this study.
You have a body mass index (BMI) of ≥ 18.
You understand the study procedures and signs forms providing informed consent to participate in the study and authorization for release of relevant protected health information to the study Investigator.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.